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ABSTRACT
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by a loss of
motor neurons in the brain and spinal cord, leading to progressive muscle weakness in multiple regions
of the body. No effective treatment is available and the disease progresses rapidly to death with an
average survival time of 3-5 years after symptom onset. The etiology of ALS is unknown for the majority
of the patients. Alterations in the carbohydrate and lipid metabolisms, together with hypermetabolism,
are features of ALS patients that are not yet well characterized. Understanding the early metabolic
symptoms of the disease might be a necessary step for the identification of an effective treatment.
Paper I describes a nested case-control study on the association between diabetes and the future
risk of ALS in the Swedish population. A total of 5,108 new ALS cases among the Swedish residents
between 1991 and 2010 were identified from the National Patient Register. Through linkages to several
nationwide Swedish registers five controls per case were selected from the entire Swedish population
using incidence density sampling and diabetes diagnoses were identified for both cases and controls
from hospital admission records, outpatient care records, prescription of antidiabetics, or a combination
of the three. An overall inverse association between diabetes and risk of ALS was found. There was
however a positive association between insulin-dependent diabetes before age 30 and ALS risk.
Paper II describes the association between body mass index (BMI), BMI change and ALS risk and
survival in the GENEVA study, a case-control study of United States military veterans. Self-reported
BMI at age 25, 40 and at time of ALS diagnosis (interview for controls) was compared. Low BMI at
age 40 was associated with increased risk of developing ALS and the association was stronger for cases
with diagnostic delay shorter than one year. Stable or decreasing BMI between age 25 and 40 was also
associated with higher risk of ALS compared to an increasing BMI. However, premorbid BMI and BMI
change did not predict survival of ALS patients.
Paper III describes the association between ALS risk and serum glucose, total cholesterol, LDL-C,
HDL-C, triglycerides, apolipoprotein B (apoB), and apolipoprotein A-I (apoA-I) in a Swedish population-
based cohort study. High LDL-C, apoB and the LDL-C/HDL-C and apoB/apoA-I ratios were associated
with a higher incidence of ALS. These associations seemed to be mainly due to a strong association of
apoB with ALS risk. High glucose level (≥6.11 mmol/L) was associated with a lower incidence of ALS.
During the 10 years before diagnosis, ALS patients had increasing levels of LDL-C, HDL-C, apoB and
apoA-I, whereas gradually decreasing levels of LDL-C/HDL-C and apoB/apoA-I ratios.
Paper IV describes a population-based nested case-control study of 2,475 Swedish residents diag-
nosed with ALS during July 2006-December 2013, and 12,375 population controls. Information on filled
prescriptions of antidiabetics and statins were extracted from the Swedish Prescribed Drug Register.
Antidiabetics were associated with a lower ALS risk, the association was stronger for men, for individuals
above age 65, and for ALS with longer disease duration. Statins were not associated with ALS risk overall,
though a positive association was noted among women. The latter association was mostly explained by
increased statins use during the year before ALS diagnosis.
The studies presented in this thesis have taken advantage of different study designs and populations
to systematically investigate the relationship between metabolic disorders and ALS risk and, to a lesser
extent, progression. Therefore, they contributed substantially to fill the knowledge gap about the asso-
ciation between metabolic disorders and neurodegeneration in ALS. Furthermore, Paper I and Paper
IV serve as excellent examples of the unique possibilities offered by the nationwide health registers in
Sweden that can, when equipped with modern analytical methods, contribute to the understanding of
complex diseases.
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Chapter 1
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a rather rare though highly feared neurodegenerative
disease. The rapid and irreversible progression to full body paralysis is devastating for the
patients and causes high psychological stress also for caregivers [1].
Since Jean-Martin Charcot first described the disease in 1869 a massive research effort has
been made. However, current treatment affects the disease progression only marginally and
the etiological mechanisms are still largely unclear.
The answer to the questions "Who develops ALS?", "Why?" and "When?" would indicate
the most promising targets for therapeutic intervention. ALS is likely a complex multifactorial
disease and epidemiological investigations of premorbid disease represent an important tool
to study its etiological process and suggest possible molecular pathways.
Metabolic alterations have often been reported in patients with ALS [2], as well as in studies
focusing on antecedent conditions [3]. Metabolic disorders like diabetes, dyslipidemias and
obesity may comprise resistance to neurodegenerative processes occurring in ALS. Most of
the associations linking metabolic factors to ALS are, however, still controversial and poorly
understood [4]. Studying the metabolic features of ALS can expand and refine the current
knowledge on both risk factors and prognostic indicators for ALS. Metabolic diseases may share
environmental risk factors or genetic predisposition with ALS and, furthermore, the treatments
of these diseases may alter future risk of ALS development.
In this thesis, I present four epidemiological studies that focus on different aspects of the
relationship between metabolic alterations and ALS. The factors investigated include metabolic
disorders such as diabetes, anthropometric measures such as body mass index (BMI), blood
biomarkers, and medications. The background section provides a short introduction limited to
the topics of main relevance for the presentation of the four studies. To summarize the joint
contribution of these studies, the main results, some discussion points, and thoughts on future
directions are also presented.
Chapter 2
BACKGROUND
2.1 ALS
2.1.1 Disease characteristics
ALS is characterized by a loss of motor neurons in the brain and spinal cord, leading to progres-
sive muscle weakness in multiple regions of the body [5]. The disease most commonly presents
focal symptom onset and progresses rapidly leading to fatal respiratory failure.
In all patients with ALS the disease spreads to both upper motor neurons and lower motor
neurons even if only upper of lower motor neurons may be affected at motor symptoms onset.
Degeneration of upper motor neurons causes muscle weakness, hyperreflexia, and spasticity. De-
generation of lower motor neurons in the brainstem and spinal cord results in muscle weakness,
atrophy or amyotrophy, and muscle fasciculation. Evidence is accumulating that the disease
process in ALS involves not only motor neurons but also interneurons and non-neuronal cells
such as astrocytes and microglia [6].
Spinal symptoms include difficulties in walking and in performing other body movements.
Bulbar symptoms include dysphagia and dysarthria. Recently, increasing attention has been
paid to cognitive symptoms. Some extent of cognitive impairment is nowadays recognized in
the majority of the ALS patients. The overlap between ALS and frontotemporal dementia (FTD)
is established and heterogeneous neuropsychological deficits have been reported [7, 8].
Diagnosis
There is no single confirmatory test for a suspected diagnosis of ALS. The diagnosis is usually
based both on the assessment of signs and symptoms and on the exclusion of other conditions.
The symptoms are sometimes misinterpreted and different specialists may be consulted
before referring to a neurologist. Despite muscle fasciculation, typically in the limbs or in
the tongue, is a clear sign of the disease to a specialist, establishing an ALS diagnosis most
often requires a meticulous diagnostic workup. The consequent diagnostic delay (i.e. the time
interval between symptom onset and clinical diagnosis) is on average one year [9] and is often
cause of distress to the patient.
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The current international guidelines for diagnosing ALS are the El Escorial criteria. These
criteria were first proposed by the committee on motor neuron diseases of World Federation
of Neurology in 1990 and were revised in 1998 [10].
The diagnostic work-up may consist in a neurological examination looking for upper and
lower motor neuron signs, collection of detailed family history, neuroimaging including brain
CT and MRI of the brain and spine, blood test, lumbar puncture (also to evaluate neurofilament
levels), neurophysiological examinations, neurography measuring electrical conduction in the
limbs, and electromyography examining the lower motor neurons.
Neuroimaging is used to rule out disorders such as multiple sclerosis or brain tumor. Elec-
trodiagnostic investigations are helpful in evaluating weakness, muscle wasting, and sensory
symptoms. Both upper and lower motor neuron involvement needs to be present to exclude
other even rarer motor neuron diseases such as primary lateral sclerosis, which affects the
upper motor neurons, progressive bulbar palsy, which affects the lower motor neurons in the
brain stem, and progressive muscular atrophy, which affects the lower motor neurons in the
spinal cord.
Etiopathology
Important advances have been made since Jean-Martin Charcot first described ALS in 1869.
Indeed, the identification of some genetic causal variants has led to a number of animal models
of the disease. The causes of the disease however are likely diverse, remain unknown for the
majority of the patients, and none is yet fully understood at a cellular level.
The general belief is that ALS is a complex multifactorial disease [11]. This hypothesis is
supported by the observed variation of ALS incidence with age [12].
Furthermore, it is likely that multiple different upstream mechanisms result in a final com-
mon pathway leading to the peculiar pathology of ALS [13, 14]. The cascade of pathological
events may start many years before the overt disease [15].
Some mechanisms involved in the disease include protein misfolding and aggregation,
microglial activation, oxidative stress, excitotoxicity, and impaired axonal transport (Figure
2.1) [16, 17].
Treatment
Although several compounds have shown promising results in preclinical studies, their transla-
tion into clinical trials has failed. True lack of efficacy may not be the only reason that has led
to the failure of many clinical studies [18].
The only routinely administered drug that improves survival time is riluzole (Rilutek; Aven-
tis Pharma, Antony, France)[19]. Riluzole prolongs the survival time on average by a few
months but this medication does not stop the disease course. The beneficial effect on survival
is thought to be the result of preventing glutamate-induced excitotoxicity. Adverse reactions
include asthenia, nausea, vomiting, diarrhea, abdominal pain, anorexia, dizziness, and liver dam-
age. The potentially neuroprotective Endaravone has started to be administered more recently
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Figure 2.1: Mechanisms of disease implicated in ALS. (a) Familial ALS-associated mutations frequently
affect genes that are components of the cellular protein quality control system. Other mutations, such as
those in SOD1, affect protein folding. (b) Hyperactivation of microglia produces extracellular superoxide,
which triggers inflammation and degeneration in motor neurons. (c) A reduction in the levels of the
lactate transporter MCT1 diminishes energy supplied by oligodendrocytes to motor neurons. (d) A
failure of astrocytes to clear synaptic glutamate via the transporter EAAT2 triggers repetitive firing of
motor neurons and excitotoxicity. (e) Disruption of the cytoskeleton and impaired axonal transport limits
the exchange of essential macromolecules and organelles between the neuronal cell body and distal
compartments. (f) Disturbances in aspects of RNA metabolism, including RNA processing, transport and
utilization, are largely the result of impaired hnRNP function. Reproduced with permission from Taylor
et al. (2016).
and other pharmacological treatments are under study [20, 21]. An animal study targeting
simultaneously motor neurons, astrocytes and microglia in ALS mice suggested that targeting
different pathogenic mechanisms in independent cell types may be an effective therapeutic
strategy for ALS [22].
Because ALS is progressive and incurable most current treatments for ALS are inevitably
consisting in either multidisciplinary care, to improve quality of life, or palliative care, to relieve
signs and symptoms throughout each stage of the disease. Physical and occupational therapy
is aimed to delay loss of strength, maintain endurance, prevent complications, reduce pain,
and promote functional independence. Patients can benefit from exercising which may help
improve cardiovascular health, fatigue, and depression. Speech-language pathologists can also
help patients. Placement of percutaneous gastrostomy tube for nutritional support is common
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and can prolong the survival [23]. Nearly all patients develop signs and symptoms of respiratory
insufficiency that may require mechanical ventilation. When mechanical ventilation is consid-
ered, patients can be offered either noninvasive positive-pressure ventilation or tracheostomy.
Pharmacotherapy may be indicated to treat depression and pain as well as other symptoms
like dyspnea, muscle spasm, spasticity, sialorrhea, fatigue, dysphagia, and sleeping problems.
2.1.2 Epidemiology of ALS
Incidence and prevalence
ALS is the most common motor neuron disease. About two individuals in each 100,000 develop
ALS every year [24]. The mean age at onset ranges between 60 and 70 years of age [25].
Though ALS incidence is thought to be rather similar across countries some differences
are present (Figure 2.2) [24]. Higher incidence rates have been reported consistently for older
populations, among males, and among whites [26, 27]. ALS incidence seems to be quite ho-
mogeneous in Europe though age-standardized incidence may be higher in Northern Europe
[24, 27].
With the aging of the population the yearly incidence of ALS is estimated to increase in the
Western countries to almost 4 per 100,000 in 2050 [25].
The disease progresses rapidly with an average survival time of 3–5 years after the first
symptom onset. Therefore, the disease prevalence is lower than 10 per 100,000 [28, 29]. The
prevalence is increasing as a result of the increasing incidence and the efforts for prolonging
patient survival [29].
Genetic risk factors
About 5-10% of the patients with ALS cases have a clear family history [30], while for the
other 90-95% of the patients (i.e. sporadic ALS cases), the etiology is largely unknown. The
heritability of sporadic ALS is estimated to be high [31] but attempts to establish the complex
genetic basis for sporadic ALS have had only little success.
Cytosolic copper-zinc superoxide dismutase (SOD1) was the first ALS gene to be identified
in 1993 [32]. The gene expresses the SOD1 protein which acts as an enzyme in the degradation
of reactive oxygen species. Therefore, the identification of SOD1 mutations in ALS patients
provided the first genetic basis for the oxidative damage reported in ALS. Many useful mutant
SOD1 models have been developed in different species and the mutant SOD1 mouse models
are still the most common animal model of ALS [33].
The most common known cause of ALS has been identified in 2011 as an expansion of a
hexanucleotide intronic repeat within the first intron of the chromosome 9 open reading frame
72 (C9orf72) gene [34–36]. The exact mechanism has not been elucidated yet but the toxicity
of this mutation may be due to deleterious intranuclear deposition of RNA. The recognition of
the C9orf72 mutation also provided a strong genetic common basis for the ALS-FTD spectrum
[8].
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Figure 2.2: Distribution of ALS worldwide: crude incidence and age- and sex-standardized incidence on
USA 2010 population. Reproduced with permission from Marin et al. (2016).
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To date, more than 100 gene mutations have been linked to ALS[14, 37]. Both rare and more
common genetic variants have been identified and different levels of penetrance have been
observed (Figure 2.3). The TARDBP gene expressing the Transactive Response DNA-Binding
Protein 43 (TDP-43) and the Fused in Sarcoma (FUS) gene are among the most studied ALS
genes and they are both implicated in RNA metabolism [38, 39].
Figure 2.3: Certain traits and conditions, such as height, BMI and schizophrenia, are influenced by the
cumulative effect of tens or hundreds of gene variants, each only contributing a small amount to overall
risk. Owing to the small effect of each variant, removal of these variants from the population by natural
selection is weak, and they can become common. Diseases such as cystic fibrosis or Huntington disease
result from single gene mutations that greatly increase the risk of disease. Owing to their large effects,
such variants tend to be removed from the population by natural selection and remain rare, unless,
as is the case for cystic fibrosis, they confer some selective advantage in certain environments. Genes
associated with amyotrophic lateral sclerosis (ALS) include both types, but the majority of associated
variants have an intermediate effect size. In the figure, blue areas indicate genetic variants implicated in
phenotypes other than ALS, and grey areas indicate genetic variants implicated in ALS, with the name of
the corresponding gene listed. The x-axis shows the number of genetic variants involved in a phenotype,
ranging from Mendelian (single gene variant) to polygenic (multiple gene variants). Reproduced with
permission from Al-Chalabi et al. (2017).
Some ALS genes, among which SOD1, C9orf72 and FUS, influence also factors such as ALS
phenotype (e.g. age or site of onset) and survival time. Moreover, genetic variants that are not
primary causes of ALS have been found to influence susceptibility, ALS phenotype, and survival
[14].
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Environmental risk factors
Many environmental risk factors for ALS have been studied [40, 41]. Exposure to pesticides,
pollutants and lead is recognized to increase the risk of ALS [42]. Head trauma is likely also a
risk factor [43–45].
The variation of ALS risk across occupations has been largely studied but the actual risk
factors driving the suggested associations are still uncertain [46]. One of the mechanisms sug-
gested by the higher risk associated with occupations requiring contact with public is infections
[47]. Exposures related to military service may also be dangerous but ALS risk was not found
to be increased among military personnel overall [48, 49].
Lifestyle may also play a role. For instance, following the development of ALS in well-known
athletes, extreme physical activity has been recognized as associated with an increased risk
of ALS [50–53]. Genetic variants related to energy metabolism have recently been found to
be involved in this association [54]. Moderate physical activity has however been associated
with reduced risk [53, 55, 56]. A SOD1 mouse study suggested a neuroprotective effect of
exercise via modulation of glial cells [57]. A reduced incidence of premorbid cardiovascular
disease has also been reported among ALS patients [58–60]. This association may however
be partially due to the confounding effect of healthy diet [61, 62] and smoking [63]. Indeed,
consumption of foods high in carotenoids and omega-3 long-chain polyunsaturated fatty acids
has been associated to reduced ALS risk, while smoking is likely a risk factor for ALS.
Prognostic factors
The rate of progression of ALS is difficult to predict [64]. Though treatment has a rather limited
effect, both genetic and non-genetic factors have been associated to the rate of progression of
the disease [65].
Among the markers of the disease advancement serum levels of albumin and creatinine
at the time of diagnosis were found to be inversely related to survival [66]. BMI [2, 67–70],
subcutaneous body fat [71], and lipid levels [72] all positively correlate with survival. Dietary
guidelines are not established but high fat diet is believed to extend survival [73], and intake of
fruits and vegetables has recently been suggested to slow the progression of the disease [74].
Interestingly, premorbid habits such as cigarette smoking seem to be also associated with
ALS survival after diagnosis [63, 75].
2.2 METABOLIC DISORDERS
The metabolism of an organism is defined as the sum of the physical and chemical processes
by which the material substance of the organism is produced, maintained, and destroyed, and
by which energy is made available.
When any of these processes is chronically disrupted the energy metabolism is altered and
a metabolic disorder develops. Both genetic and lifestyle factors influence the risk of metabolic
disorders and some common examples are diabetes mellitus, dyslipidemia, and obesity.
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Given the change in lifestyle, the incidence and prevalence of metabolic disorders, especially
type 2 diabetes and obesity, have been raising in the developed countries over the past decades.
Accordingly, treatment for metabolic conditions is prevalent in the Western countries and may
introduce potential unforeseen effects at the population level.
2.2.1 Diabetes
Diabetes mellitus, or simply diabetes, is one of the most common chronic diseases, with a great
impact on the individual patient and the society. Different types of diabetes have different
etiologies, all of which result in detrimental accumulation of glucose in the blood stream.
Type 1 diabetes is mainly an autoimmune disease affecting and destroying the pancreatic
beta-cells which produce insulin. This form of diabetes is usually hereditary and diagnosed
before 30 years of age.
Type 2 diabetes is characterized by insulin resistance. The large majority of patients with
diabetes suffer from type 2 diabetes which is an aging-associated disease. Other than genetic
predisposition, an unbalanced diet and a sedentary lifestyle predispose to this condition.
Treatment
A diagnosis of diabetes is always followed by lifelong treatment to prevent the deleterious
effect of high blood glucose.
While insulin is the routine treatment for type 1 diabetes, oral antidiabetics are the initial
treatment option for type 2 diabetes. Nevertheless, patients with type 1 diabetes can be pre-
scribed with other antidiabetic medications and insulin therapy is often beneficial to patients
with severe type 2 diabetes.
2.2.2 Dyslipidemia
Perturbations of lipid metabolism result in dyslipidemias, i.e. abnormal lipid levels in the blood.
The large majority of patients with dyslipidemias have a form of hyperlipidemia. The most
common forms are hypercholesterolemia and hypertriglyceridemia.
Treatment
Lipid-modifying agents are largely used as pharmacological treatment of hyperlipidemia. Statins
are 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors used to treat hypercholes-
terolemia and represent one of the most commonly prescribed medications worldwide [76].
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2.3 METABOLISM AND ALS
2.3.1 Metabolism before motor symptom onset
Epidemiological studies investigating the biological processes occurring before the overt dis-
ease are difficult to perform. However, some successful attempts of assessing in humans the
hypotheses generated by preclinical studies have been made.
Epidemiological studies
Several studies reported an association between lower BMI and increased risk of developing
ALS [77, 78]. This association may exist also for BMI during youth, i.e. decades before the
onset of motor symptoms [78]. Increased resting energy expenditure before clinical onset of
ALS was reported by a Dutch study [79].
Premorbid type 2 diabetes was found to be associated with a 4-year later onset of ALS [80]
whereas type 1 diabetes may be associated with increased risk of ALS [81].
Animal studies
Mutant SOD1 mice present presymptomatic hypermetabolism and reduced adipose tissue ac-
cumulation [82]. Hypolipidemia [83] and inhibition in the capacity of glycolytic muscle to use
glucose [84] were also observed in mutant SOD1 mice.
2.3.2 Metabolism after motor symptom onset
Metabolic alterations among patients with ALS have been reported for decades [85].
Hypermetabolism is generally recognized as an established and early feature among ALS
patients [2, 86–89]. The causes underlying this accelerated metabolism have however not
been completely understood. One of the contributing mechanisms may be the presence of
fasciculation which contributes to the increased energy expenditure [90].
Alterations in both carbohydrate (e.g. impaired glucose tolerance) and lipid (e.g. dyslipi-
demias) metabolisms have been reported [91].
Insulin resistance and possibly hypermetabolism are features appearing consistently across
the ALS-FTD spectrum [92]. However, ALS and FTD show opposite trends for BMI [93]. Despite
the common genetic predisposition of ALS and FTD, weight loss is typical of ALS and the
presence of cognitive deficits is associated with a tendency towards weight gain. Interestingly,
ALS progression has been suggested to impair responsiveness to classical drugs leading to
weight gain [94].
More insights on metabolic alterations occurring in ALS have been suggested by animal
studies. For instance, the mutant SOD1 mouse exhibits increased peripheral lipid clearance
[95]. Further, lipid accumulation in neurons was found in Spg11 knockout mice that have been
proposed as a model for ALS [96].
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2.3.3 Metabolic disorders as risk factors
Risk of ALS
Different hypotheses have been formulated for the association of physical activity and bene-
ficial cardiovascular profile with ALS [59]. The common belief has been shifting towards the
hypothesis that the metabolic profile may be a common cause of ALS and cardiovascular health
(Figure 2.4). Indeed, preclinical studies have suggested a causative effect of defective energy
metabolism on the peripheral nervous system. Muscle-restricted mitochondrial defect which
results in energy deficiency has been shown to cause the destruction of the neuromuscular
junction and subsequently induce motor neuron death [97, 98].
Medications used for treatments of metabolic disorders may be associated with the devel-
opment of ALS independently. For example, analyses of surveillance databases have suggested
that statin use might be associated with the occurrence of an ALS-like syndrome [99, 100].
However, other studies have reported a null association between statins and ALS risk [101].
Figure 2.4: Proposed concept shift in the pathogenic mechanisms of ALS. From (A) a genetically deter-
mined fitness profile, by means of increased physical activity, increases the risk of ALS and decreases the
risk of cardiovascular diseases and risk factors; via (B) where both increased ALS risk and cardiovascular
fitness are the result of a common genetic predisposition; towards (C) where an increased ALS risk, and
fewer cardiovascular risk factors are the result of a specific pathway, modified by genetic predisposi-
tion, possibly in combination with exogenous risk factors (such as physical activity). Reproduced with
permission from Visser et al. (2017).
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ALS progression and survival
Rate of progression of motor symptoms correlates with weight loss [102]. Low lipid levels were
a negative prognostic factor in some studies but not in others [72, 103, 104]. The associations
between ALS progression or survival and diabetes (permorbid or during the course of the
disease) have rarely been studied in population-based studies. However, a recent study reported
a null association between premorbid type 2 diabetes and survival in a large sample of ALS
patients that had participated in clinical trials [105].
The recognition of the interrelation between metabolism and disease progression has al-
lowed the identification of therapeutic targets [106]. Some therapies that target the metabolism
have shown encouraging effects in animal models but evidence from clinical trials supporting
the efficacy of these therapies in slowing the disease progression is still limited [106].
Chapter 3
AIMS
This thesis sought to provide insight into pre-diagnosis metabolic features of ALS patients with
the purpose of identifying high-risk groups and elucidating the etiopathogenesis of the disease.
The specific aims of the thesis are as follows:
• To evaluate whether diabetes is associated with future risk of ALS and the temporal
pattern of this association (Paper I).
• To confirm the epidemiological evidence of an inverse association between BMI, weight
gain and ALS risk, and investigate if pre-diagnosis BMI predicts ALS survival (Paper II).
• To assess the associations of several blood biomarkers of carbohydrate, lipid and apolipopro-
tein metabolisms with the future risk of ALS (Paper III).
• To describe whether the prescriptions of antidiabetics and statins are associated with
future risk of ALS in Sweden (Paper IV).
Chapter 4
MATERIALS
All the papers presented in this thesis are based, entirely or partially, on register data. Addi-
tionally, Paper II is based on the data collected for the GENEVA study and Paper III is based on
the data collected for the AMORIS study.
4.1 REGISTER DATA
The systematic collection of information in registers is a cornerstone for epidemiological re-
search. In Sweden, local population registers started to be compiled back in the 17th century.
However, it is since 1947, when Swedish National Registration Numbers identifying each and
all Swedish residents were introduced, that a number of registers developed [107]. This early
resolution to register information results nowadays in a unique opportunity of linking high-
quality individual-level data with national coverage, as shown in Paper I, Paper III and Paper
IV.
Paper II would have not been possible without the effort by the US Department of Veterans
affairs to establish the National Registry of Veterans with Amyotrophic Lateral Sclerosis that
aimed to identify and monitor veterans with ALS.
4.1.1 The Swedish Multi-Generation Register
During 1947 and 1948 personal and parental information (i.e. biological mother and father)
of all children and teenagers 15 years or younger was collected from all parish registries in
Sweden [108]. The Swedish National Registration Numbers were used as the unique identifiers
to link mother and child, or father and child [107]. Since then and until 1991, all babies born
in Sweden and all individuals immigrating to Sweden have been registered at local level for
national registration. The Swedish Multi-Generation Register was based on this information
and was computerized in 1991. The first computerized version, however, included the persons
that have been included in a census (that started in 1961) and that were still alive on June
30, 1991, or born in 1920 or after, if they had emigrated. In 2000, additional information
concerning data on the biological parents of deceased or emigrated individuals and adoptive
parents was retrieved and added to the database.
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4.1.2 The Swedish Patient Register
The Swedish National Board of Health and Welfare started collecting clinical information on
hospital admissions in the Swedish Patient Register in 1964 [109]. The information collected
includes for instance the dates of admission and discharge, the main diagnosis at discharge, and
up to 21 secondary diagnoses. All diagnoses are coded according to the Swedish Revisions of
the International Classification of Diseases (ICD). First, ICD-7 codes were used (before 1969),
then ICD-8 codes were in use from 1969 to 1986, ICD-9 codes from 1987 to 1996, and ICD-10
codes have been employed since 1997 (except for the county of Skåne that used ICD-9 in 1997
and switched to ICD-10 only in 1998) [109]. The register has full national coverage since 1987.
The collection of hospital-based outpatient physician visits of non-admitted patients, which
started in January 2001, constituted an important development of the register.
4.1.3 The Swedish Prescribed Drug Register
Since the 1st July 2005 the Swedish Prescribed Drug Register includes the Swedish National
Registration Numbers allowing individual-level information [110]. Detailed information on
drugs dispensed in all Swedish pharmacies is collected. During the first 10 years 891 million
prescriptions were recorded [111].
The recorded information includes the substance, brand name, formulation, package, dis-
pensed amount, dosage, and drug classification code according to the Anatomical Therapeutic
Chemical (ATC) classification system. Both date of prescription (a useful proxy for date of
diagnosis of the underlying medical condition) and date of dispense (a useful proxy for date
of medication use) are collected in the register.
Medicines that are prescribed but never dispensed, medicines that can be purchased without
a prescription (i.e. over-the-counter drugs), and drug treatment in clinics are not recorded in
the register.
4.1.4 The Swedish Cause of Death Register
The National Board of Health and Welfare compiles the Swedish Cause of Death Register. The
Register carries detailed information about deaths of all individuals registered in Sweden at
the time of death. Mortality data are available since 1961, regardless of whether the death
occurred in Sweden or abroad.
4.1.5 The National Registry of Veterans with Amyotrophic Lateral Sclerosis
The US Department of Veterans affairs established the National Registry of Veterans with ALS
in 2003 [112]. The Registry was established to address a growing concern about an increased
risk of ALS among military veterans, especially after the reports of a potential excess risk of
ALS among the veterans of the 1990–1991 Persian Gulf War [113]. Between April 1, 2003 and
September 30, 2007 potential patients with ALS among the military veterans were recruited and
their medical record were reviewed by neurologists to confirm the diagnosis before enrollment
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in the register. A total of 2,122 patients were enrolled in the Registry and were contacted every
6 months for follow-up interviews until September 30, 2009. Both incident and prevalent ALS
cases were included.
Veterans with ALS were identified by searching the national electronic medical record
databases of the Department of Veterans Affairs and with active recruitment through nationwide
publicity efforts. The medical record review was conducted by collecting information from all
healthcare providers and facilities in which patients had received care.
At baseline, the Registry collected the diagnosis date and type (clinically definite ALS,
clinically probable ALS, clinically possible ALS, progressive muscular atrophy, progressive bulbar
palsy), family history, onset date and site, ALS Functional Rating Scale (ALSFRS-R), and other
clinical features.
4.2 OTHER SOURCES
4.2.1 The GENEVA study
A potentially increased risk of ALS after deployment prompted the Department of Veterans
Affairs not only to establish the National Registry of Veterans with ALS but also to conduct the
Genes and Environmental Exposures in Veterans with ALS (GENEVA) case-control study [114].
From 2005 to 2010, GENEVA recruited 630 neurologist-confirmed ALS cases among the patients
that were enrolled in the National Registry of Veterans with Amyotrophic Lateral Sclerosis
between 2003 and 2007, as well as a representative sample of 975 veteran controls from the
database of all US veterans with a release of active duty [114]. The controls were frequency-
matched to the ALS patients by age and use of the Veteran Affairs system for health care (before
ALS diagnosis for the cases) as a proxy for socioeconomic status. Sex and race/ethnicity could
not be used as matching factors because this information was not available in the databases of
the Department of Veterans Affairs.
For both ALS cases and controls, a detailed structured telephone interview was conducted
to ascertain in a retrospective fashion the exposure history before their reference date. The
reference date was defined as the date of ALS diagnosis for the ALS cases and the interview
date for the controls. In case of impairment (in communication or cognition) of the GENEVA
participant, the telephone interview was conducted with a person communicating with the
participant (138 ALS cases and one control). The GENEVA interview was conducted with a
proxy for 34 deceased cases. If preferred by the patient or by the proxy respondent the interview
was conducted over multiple phone calls.
The dates of death of the ALS cases were obtained both from the National Registry of
Veterans with ALS (until September 2009 only) and from the validated Austin Vital Status File,
which is also compiled by the Department of Veterans Affairs from several sources [115].
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4.2.2 The AMORIS study
With joint efforts Ingmar Jungner at the Central Automation Laboratory (CALAB) laboratory
(Stockholm, Sweden) and Göran Walldius at Karolinska Institutet (Stockholm, Sweden) started
the Apolipoprotein MOrtality RISk (AMORIS) study. The AMORIS cohort was established with
the aim of investigating common metabolic and inflammatory blood biomarkers in relation
to different chronic diseases [116]. This cohort consists of 812,073 Swedish men and women
that were living predominantly in Stockholm and that had at least one blood or urine test
between 1985 and 1996. None of the participants was admitted as inpatient at the time of the
sample. All samples were gathered through either general health check-ups or via referral from
outpatient visits.
All fresh samples were analyzed by one and the same CALAB laboratory. More than 500
different laboratory tests were performed for a total of more than 35 millions measurements.
Information on some biomarkers (e.g. serum glucose, total cholesterol and triglycerides) is
available for the majority of the participants whereas other parameters are available only for
a limited number of participants. The test results, including the levels of different biomarkers,
were recorded in the CALAB database. This database has been linked to 24 Swedish registries,
including the Swedish Patient Register.
Chapter 5
METHODS
5.1 STUDY DESIGNS
In medical research, the choice of the most suitable study design to answer a specific research
question depends on the feasibility of different approaches. Both ethical and practical aspects
limit the conduction of scientific studies. For instance conducting a clinical trial of a potentially
beneficial but potentially harmful treatment on healthy volunteers is unethical and interviewing
the global population is utopian, even if these approaches would provide desirable answers.
In epidemiology, some scientific questions are more suitable to be answered through obser-
vational studies, while other questions are better addressed by experimental studies. A careful
evaluation of the potential confounders should be undertaken before choosing a study design.
Directed acyclic graphs (DAGs) are helpful tools for the identification of factors that need to
be controlled for in order to estimate unbiased associations [117]. Both observational and
experimental studies are needed for scientific knowledge to advance efficiently. This thesis is
based on observational studies that had different study designs. In particular, Paper I and Paper
IV were based on nested case-control studies, Paper II was based on a case-control study and
on a cohort study, and Paper III was based on a cohort study and on a nested case-control study.
5.1.1 Cohort studies
An epidemiological cohort study enrolls a group of individuals, i.e. a cohort, and follows them for
a defined time interval to ascertain an outcome of interest. Following the cohort prospectively
allows the collection of the desired information before the outcome of interest takes place.
Sometimes the same information may be collected retrospectively, though recall bias often
affects the quality of data collected retrospectively. Some information cannot be collected
retrospectively. This is for instance the case of tissue specimens for the quantification of a
biomarkers that change over time.
Under certain conditions conducting a cohort study may not be efficient. Obviously, a long
follow-up is needed for investigating exposures occurring many years before the outcome.
Furthermore, if the outcome of interest is a rare disease such as ALS, a large cohort is needed to
include a relevant number of individuals that will develop the outcomes. The desirable cohort
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sample size should be planned with care because it depends not only on the outcome but also
on the distribution of the exposure and on the distribution of the confounders in the cohort.
5.1.2 Case-control studies
Traditionally, an epidemiological case-control study enrolles a group of individuals with a
specific condition, i.e. the cases, and a group of individuals without the specific condition, i.e.
the controls, and aims to ascertain the exposure of interest for each of these individuals that
constitute the study sample. This study design is more efficient than a cohort study when the
condition of interest is rare in the population under study. The study efficiency can be enhanced
by matching the controls to the cases on known or potential confounders of the association
between the exposure and the outcome of interest, for instance age and sex. A smaller sample
size, compared to a cohort study design, facilitates the collection and management of detailed
information in case-control studies.
Case-control studies should be planned carefully to reduce the sources of bias. The selection
of controls may result in selection bias [118]. This occurs if the controls do not represent the
general population giving rise to the cases. For instance if all patients hospitalized for a certain
medical condition represent the cases, randomly recruiting the controls among the hospital
personnel is likely unsuitable to study the relationship between socioeconomic status and the
disease of interest, whereas it may be more suitable for the investigation of other factors, such as
the presence of a genetic variant. Retrospective ascertainment of exposure and confounders may
result in information bias. For example, either non-differential or differential misclassification
often occurs when the participants are asked to recall their past behaviours. It is not unexpected
that ALS patients may reflect on their past habits more than healthy controls, which may tend
to report lower frequency of many exposures only because less likely to recall correctly [119].
5.1.3 Nested case-control studies
The nested case-control design is a peculiar type of case-control design that is characterized by
some of the advantages of both cohort and traditional case-control designs. The study design
consists in conducting a case-control study based on a parent cohort. All cases that arise from
the cohort are included in the study sample. Further, a pre-defined number of controls (usually
not more than 5) are randomly selected from the cohort and individually matched to each
case. These controls must be free of the condition of interest at the time of the development
of such condition by the index case. Additional matching for potential confounders can also
be performed easily by restricting the sampling to a matched subcohort. When the population
itself is the parent cohort a population-based nested case-control study is performed. The use
of a nested case-control study is an especially efficient choice when the outcome of interest is
rare and the parent cohort is large. Indeed, not including all members of the parent cohort save
additional work or computational time. In case of a population-based study this design also
provides the ideal framework to sample the controls at random because the parent population
is known. Therefore, selection bias is less of a concern compared to the traditional case-control
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design.
However, selection bias is a possible source of bias also in nested case-control studies. As in
any matched study design, the selection bias could also be due to overmatching if the matching
precludes the representativeness of the controls [120].
5.2 STATISTICAL METHODS
5.2.1 Paper I
A population-based nested case-control study was conducted using national register data. The
Swedish population at risk of developing ALS on 1st January 1991 was identified through the
1990 Census. A total of 5,108 new diagnoses of ALS were identified in this population during
1991–2010. The ALS diagnoses were extracted from the Swedish Patient Register and both the
ICD-9 code 335.2 (between 1987 and 1997) and the ICD-10 code G12.2 (from 1997) were used
for defining ALS. Each ALS patient with first diagnosis of ALS after 1990 was included as a case
and the first date of diagnosis was defined as the index date. Subsequently five individually
matched population controls per case were sampled using incidence density sampling and
further matching on year of birth, sex, and area of residence. Area of residence was defined as
Northern, Central, or Southern Sweden as a proxy for lifestyle-related exposures. Information
on diabetes was retrieved from both the Swedish Patient Register (ICD-7 code 260, ICD-8 and
ICD-9 codes 250, and ICD-10 codes E10–E11) and the Swedish Prescribed Drug Register (ATC
codes A10A-A10B).
To specifically study differences between insulin-dependent diabetes (ICD-10 code E10)
and non-insulin-dependent diabetes (ICD-10 code E11) a three-level variable was defined (no
diabetes, insulin-dependent diabetes, or non-insulin-dependent diabetes). The time interval
between first diabetes diagnosis and index date (i.e. duration of diabetes) was computed to
study the variation of the association between diabetes and ALS risk with duration of diabetes.
Conditional logistic models were used to compute adjusted odds ratios (ORs) and corre-
sponding 95% confidence intervals (CIs) for the association between history of diabetes and
subsequent risk of ALS. The presence of interaction between diabetes and other factors was
tested not only by introducing interaction terms in the models but also by computing the rela-
tive excess risk for interaction (RERI) [121, 122]. The presence of an association for different
time windows before ALS diagnosis was first tested by introducing in the multivariable models
an arbitrarily chosen categorical variable (no diabetes, 0–2, 2–4, 4–6, 6–8, 8–10, 10+ years)
and then by introducing cubic regression splines with 5 knots, instead of the categorical variable
[123, 124].
To evaluate whether the results were likely to suffer from selection bias due to chance
sampling of non-representative controls, the sampling was repeated 100 times and the main
result was computed in all these samples for comparison.
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5.2.2 Paper II
From the total GENEVA sample patients with diagnosis of motor neuron disease other than ALS
or clinically possible ALS were excluded because the evidence for ALS diagnosis was deemed
insufficient. Two ALS patients that were younger than 25 years of age at their ALS diagnosis
were also excluded.
Logistic regression was used to estimate ORs and 95% CIs for the association of pre-
diagnosis BMI at ages 25 and 40 and BMI change with risk of ALS in the GENEVA case-control
study. Multinomial logistic regression was used to study whether the associations were compa-
rable for ALS with spinal and bulbar site of symptom onset, or for ALS with different diagnostic
delay (short: 1 year or less; moderate: 1–3 years; long: >3 years). The hypothesis underlying
the grouping of patients with ALS by diagnostic delay is that forms of ALS that tend to be
diagnosed with different delay, as well as ALS with spinal compared to bulbar site of symptom
onset, may be differently associated with premorbid BMI.
Further, the cohort of 467 patients with definite or probable ALS was followed from the
GENEVA interview to investigate the association of BMI at ages 25 and 40 with survival after
ALS diagnosis. Time since symptom onset would have been an alternative time-scale but this
information was self-reported and therefore less complete and potentially less accurate. Hazard
ratios (HRs) and corresponding 95% CIs were obtained from Cox proportional hazards regres-
sion models with time since diagnosis as the underlying time scale and closing the follow-up
on the date of death or July 25, 2013, whichever occurred first. Because only patients that
were still alive at the GENEVA interview were included in this analysis, the survival data are
left truncated at the GENEVA interview. Therefore, the patients entered the risk set (i.e. were
considered at risk of dying) only at the date of the interview. Indeed, if the patients contributed
survival time since their diagnosis immortal time bias would be introduced. The assumption
of proportional hazards over time was investigated using the χ2 test based on Schoenfeld
residuals and flexible parametric survival models [125]. To better understand the relationship
between BMI and ALS, adjusted linear regression models were estimated to investigate the
variation of the age at ALS diagnosis in function of BMI and BMI change.
A sensitivity analysis restricted to cases diagnosed within two years before the GENEVA
interview was conducted. Indeed the patients interviewed more than two years after diagnosis
were not only more likely to be long-surviving patients but they were also more likely to
recall faultily (during the GENEVA interview) episodes that occurred before diagnosis and to
misreport their past BMI or related exposures.
5.2.3 Paper III
First, a cohort study was conducted using the information collected in the AMORIS study to
investigate the future risk of ALS associated with serum levels of glucose, fructosamine, choles-
terol, HDL-C, LDL-C, triglycerides, apolipoprotein A-I, and apolipoprotein B. The AMORIS par-
ticipants with measurements of these biomarkers of interest during 1985-1996 were followed
from the date of their first blood sampling until 2011 to identify the newly diagnosed patients
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Figure 5.1: Flow chart of the selection process, a more than 20 year follow-up of the Swedish AMORIS
Study.
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with ALS according to the Swedish Patient Register (ICD-8 code 348,00, ICD-9 code 335.2, and
ICD-10 code G12.2). The participants that had emigrated or were diagnosed with ALS before
the blood sampling of the biomarker of interest were excluded (Figure 5.1) and the follow-up
time was censored at death, emigration, and December 31, 2011, whichever occurred first. HRs
and corresponding 95% CIs were estimated using adjusted Cox models with attained age as
the underlying time scale. The assumption of proportional hazards over different ages was
investigated using the χ2 test based on Schoenfeld residuals and flexible parametric survival
models [125].
Secondly, a nested case-control study based on this subcohort of the AMORIS cohort was
performed to further investigate how the concentrations of the biomarkers varied during the
20 years before ALS diagnosis (Figure 5.1). Using incidence density sampling 25 controls for
each of the 623 ALS cases were randomly chosen from the participants of the cohort study
with same sex, year of birth, and similar time of enrollment in the AMORIS cohort (within
one year before or after the index case). All repeated measurements of the biomarkers before
index date (i.e. ALS diagnosis for cases and ALS diagnosis of the index case for controls) were
considered in this analysis. For the cases and the controls the mean concentrations of different
biomarkers by time to index date were plotted using locally weighted scatterplot smoothing as
a graphical summary of the biomarker levels in these two groups. Adjusted linear mixed-effect
models were fitted to formally test differences in the variation of the biomarkers level during
the 20 years before index date between ALS cases and controls.
5.2.4 Paper IV
A population-based nested case-control study was designed similarly to the study conducted for
Paper I. This study investigated the association of antidiabetics and statins with the subsequent
risk of ALS using information on all 2,475 newly diagnosed patients with ALS between July 2006
and December 2013 in the Swedish Patient Register (ICD-10 code G12.2) and 5 individually-
matched population-controls per case. For each study participant all filled prescriptions of
antidiabetics drugs (ATC code A10) and statins (ATC code C10AA) between July 2005 and
December 2013 were extracted from the Swedish Prescribed Drug Register, as proxy for use of
these medications.
Index date was defined as the date of first ALS diagnosis for the cases and the date of ALS
diagnosis of the index case for the controls. Binary variables indicating ever use of antidiabetics
or statins before index date were computed for cases and controls.
If the first prescription of a medication was within one year from the date of the estab-
lishment of the Swedish Prescribed Drug Register (i.e. before July 1, 2006), the time of first
prescription was considered left-censored and the participant was defined as prevalent user,
irrespectively of the time interval between first prescription and index date. Conversely, if the
first prescription occurred on or after July 1, 2006, the participant was defined as new user. For
new users, a categorical variable for the number of years between first prescription and index
date (<1 year, 1-2, 2-3, 3-4, 4-5, or 5-8 years) was considered in the analysis as an alternative
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way to define medication use.
Additional linkages between registers allowed an attempt of grouping ALS patients in more
homogeneous subgroups. The Swedish Cause of Death Register was used to categorize the
patients that had not survived more than one year after diagnosis as with short ALS duration and
patients with slower disease course as with long ALS duration. The Swedish Multi-Generation
Register was used to identify first and second degree relatives of ALS patients. ALS patients
were defined as familial cases if at least one of the identified relatives was also diagnosed with
ALS according to the Swedish Patient Register.
Conditional logistic models were used to compute adjusted ORs and corresponding 95%
CIs for the association between the different medications and subsequent risk of ALS.
Chapter 6
MAIN RESULTS
6.1 RISK OF ALS
6.1.1 Diabetes (Paper I)
Among the 5,108 ALS cases 224 (4%) had diabetes before their ALS diagnosis and among
the 25,540 controls 1,437 (6%) had diabetes before the ALS diagnosis of their index case.
An inverse association between history of diabetes and risk of ALS was suggested also after
adjustment for sex, age, area of residence, years of education, and socioeconomic status (OR:
0.79; 95% CI: 0.68–0.91). Results were comparable for men and women (Table 2 in Paper I).
Results by age
This association between diabetes and subsequent ALS was highly age-specific. Compared to
matched controls, individuals with diabetes had a significantly higher risk of developing ALS
before age 50 (adjusted OR: 3.15; 95% CI: 1.40–7.08) but a lower risk of developing ALS after
age 70 (Table 2 in Paper I). When comparing diabetes with diagnosis before and after age 30,
diabetes before age 30 was positively associated with ALS risk (adjusted OR: 3.25; 95% CI
1.61–6.53) while diabetes later in life was inversely associated with ALS risk (adjusted OR:
0.74; 95% CI 0.63-–0.85).
Insulin dependence status
Insulin-dependent diabetes was not clearly associated with risk of ALS diagnosis at any age
(adjusted OR: 0.83; 95% CI: 0.60—1.15) but it was positively associated with risk of ALS
before age 50 (adjusted OR: 5.38; 95% CI: 1.87—15.51). Conversely, for non-insulin-dependent
diabetes the positive association with risk of ALS before age 50 was not as strong as for insulin-
dependent diabetes (adjusted OR: 2.12; 95% CI: 0.37—12.10) and inverse associations were
reported for all other age categories (Table 3 in Paper I).
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Diabetes duration
The spline curve modelling the variation of the OR of ALS by duration of diabetes suggested a
U-shaped trend (Figure 2B in Paper I). The model showed that the lowest risk of developing ALS
was about 6 years after the ascertainment of diabetes. Right after the diagnosis of diabetes and
more than 8 years after the diagnosis of diabetes the risk of ALS was higher but still decreased
compared to individuals without diabetes.
Because early onset diabetes was positively associated with ALS, it was not surprising that
the protective effect of long-standing diabetes was stronger after excluding the individuals
with diabetes onset before age 30 (Figure 2C in Paper I). The protective effect of long-standing
diabetes may be limited to type 2 diabetes but the statistical power to test this hypothesis
directly in the data was low.
6.1.2 BMI and BMI change (Paper II)
The analysis sample included 975 controls and 467 ALS cases from the GENEVA study with
non-missing information on BMI.
At ALS diagnosis the cases were thinner compared to their matched controls at the same
age, after adjustment for age, sex, race/ethnicity, use of the Department of Veterans Affairs
system for health care, cigarette smoking, and years of education (Table 2 in Paper II). A similar
trend was observed for BMI at age 40 but no clear association with ALS was found for BMI at
age 25. The results for BMI at age 40 did not seem to be highly influenced by reverse causation.
Only 27 (5%) of the veterans with ALS diagnosis after age 40 were younger than 45 years old
at diagnosis and the association was similar after excluding these patients from the analysis
(adjusted OR: 0.96; 95% CI: 0.92, 0.99).
Furthermore, BMI change between age 25 and age 40 seemed to differ between patients
with ALS and matched controls, also after additional adjustment for and BMI at age 40 (Table
3 in Paper II). ALS patients were more likely to experience weight loss or stable weight (weight
change less than 0.5 kg/m2) compared to the controls. Moderate increase in BMI (between
0.5 and 3.5 kg/m2) presented a similar decreased risk of ALS as substantial increase in BMI
(more than 3.5 kg/m2).
Results for ALS subgroups
The association between BMI and ALS with bulbar site of onset was similar to the association
between BMI and ALS with spinal site of onset (Table 4 and Web Table 1 in Paper II). Conversely,
the association of ALS with BMI seemed to vary by diagnostic delay (Figure 6.1). Indeed, the
patients with short diagnostic delay (1 year or less between symptom onset and diagnosis) were
thinner then controls both at date of diagnosis (adjusted OR: 0.89; 95% CI 0.85—0.92) and at
age 40 (adjusted OR: 0.91; 95% CI: 0.87–0.96), whereas the BMI of patients with diagnostic
delay longer than 3 years was similar to controls also at the date of diagnosis (adjusted OR:
0.95; 95% CI 0.85—1.00).
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Figure 6.1: ORs and 95% CIs for the association between BMI at age 40 (kg/m2) and ALS risk according
to site of onset and diagnostic delay, adjusted for age, sex, race/ethnicity, use of the Department of
Veterans Affairs system for health care, cigarette smoking, and years of education.
6.1.3 Carbohydrate, lipid and apolipoprotein metabolisms (Paper III)
During the follow-up of the 636,132 AMORIS participants that met the study inclusion crite-
ria, 623 individuals received a diagnosis of ALS. As older age and male gender are generally
associated with an increased ALS risk, ALS patients were on average 8 years older at the time
of first blood sampling and more likely to be male (63% versus 51%) compared to the rest of
the cohort.
The HRs of ALS for a unit increase of the biomarkers suggested a positive association with
ALS risk for LDL-C, apoB, and the apoB/apoA-I ratio after adjustment for sex, age at first blood
sampling, fasting status (overnight fasting versus non-fasting), occupation, and country of
birth (Table 3 in Paper III). When categorizing the biomarker levels according to published
guidelines in cardiovascular prevention, high glucose level (≥6.11 mmol/L) was associated
with decreased ALS risk (adjusted HR: 0.62; 95% CI: 0.42–0.93) whereas high LDL-C/HDL-C
ratio (≥3.5) and high apoB/apoA-I ratio (≥0.9 for men and ≥0.8 for women) were associated
with increased ALS risk (Table 4 in Paper III). The associations between the biomarkers and
ALS tended to be stronger among females compared to males (Supplementary Table 2 in Paper
III).
The comparison of the 623 AMORIS participants newly diagnosed with ALS during follow-
up with the 15,575 individually matched controls highlighted some differences in the biomark-
ers levels over time. During the 10 years before diagnosis, ALS patients had increasing levels
of LDL-C, HDL-C, apoB and apoA-I. Because the increases of HDL-C and apoA-I were more
marked compared to the increases in the LDL-C and apoB levels, the LDL-C/HDL-C ratio and
the apoB/apoA-I ratios were decreasing during the 10 years before diagnosis. The increase
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was statistically different for cases compared to controls for apoA-I (p-value for interaction =
0.02) after adjustment for fasting status and match-set and subject specific effects.
Results for ALS subgroups
The associations between the biomarkers and ALS were stronger both among individuals that
were 55 years and above at blood sampling (Supplementary Table 1 in Paper III) and for ALS
diagnosed at age 65 or above (Table 6.1).
Table 6.1: HRs and 95% CIs of ALS at age 65 or older for biomarkers of carbohydrate, lipid, and apolipoprotein
metabolism by attained age, after adjustment for sex, age at measurement, fasting status, occupation and country
of birth, a more than 20 year follow-up of the Swedish AMORIS Study.
Person-years No. of ALS cases HR (95%CI)
Biomarkers of carbohydrate metabolism
Glucose (mmol/L) 2 245 148 301 0.88 (0.78–0.99)
Biomarkers of lipid metabolism
HDL-C (mmol/L) 1 031 364 153 0.81 (0.56–1.16)
LDL-C (mmol/L) 1 031 715 153 1.25 (1.09–1.43)
LDL-C/HDL-C ratio 1 028 062 153 1.08 (1.00–1.15)
Biomarkers of apolipoprotein metabolism
ApoA-I (g/L) 941 893 133 0.60 (0.28–1.29)
ApoB (g/L) 884 589 130 2.03 (1.30–3.18)
ApoB/ApoA-I ratio 840 551 123 2.42 (1.48–3.96)
6.1.4 Antidiabetics and statins (Paper IV)
The assessment of drug prescriptions was left truncated because the Swedish Prescribed Drug
Register was established only in July 2005, and participants with prescriptions of antidiabetics
or lipid-lowering drugs only before this date were misclassified as never prescribed. However,
all participants had an interval of time when information on drug prescriptions was available
of at least one year and discontinuation from these medications is rather low. Indeed, 94% of
the participants that were prescribed with antidiabetics in 2006 and 81% of the participants
that were prescribed with statins in 2006 were also prescribed with antidiabetics and statins,
respectively, in 2007.
Only 7% of the 2,475 Swedish residents diagnosed with ALS had filled a prescription of
antidiabetics before the ALS diagnosis while 9% of the 12,375 population controls had filled
a prescription before their index case diagnosis. In this sample the prescription of antidia-
betics was associated with a lower future risk of ALS (OR: 0.76; 95% CI: 0.65–0.90) after
adjustment for age, sex, and area of residence. The association did not vary largely by sex, age,
and in presence of family history. However, a null association was found for first antidiabetic
prescription during the 8 years before ALS diagnosis (new users)(adjusted OR: 1.00, 95% CI:
0.77–1.30). The inverse association of antidiabetics with future ALS risk was therefore driven
by the decreased risk of ALS that was noted for the prevalent users (adjusted OR=0.66, 95% CI:
0.54-0.81), suggesting that less than 8 years of diabetes may not be enough to be protective.
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Among the ALS cases 29% had filled a prescription of statins before the ALS diagnosis
while 27% of the controls had filled a prescription before their index case diagnosis. A positive
association between the prescription of statins and ALS risk was limited to the year before ALS
diagnosis (Figure 1 in Paper IV). A stronger association was noted among women (adjusted OR:
2.54; 95% CI: 1.84–3.49), though an increased use of statins during the year before diagnosis
was present also in men (adjusted OR: 1.44; 95% CI: 1.04–1.98).
6.2 ALS SURVIVAL
6.2.1 BMI and BMI change (Paper II)
Among the 460 veterans with ALS that were still alive at the GENEVA interview, 72% died during
the follow-up and the average time at follow-up was 3 years. In this sample, the patients with
higher BMI at diagnosis tended to survive longer (Table 6 in Paper II), after adjustment for
age at diagnosis, diagnostic delay, riluzole use, and symptom onset site. There was however no
clear association between BMI at age 40 (before diagnosis) and survival (Table 6 in Paper II)
after adjustment for date of birth and diagnostic delay. The proportional hazards assumption
was not met for the categories of BMI at diagnosis, and the decreased risk for overweight and
obese seemed to be limited to the first 2 years after diagnosis (Figure 6.2).
Figure 6.2: Time-varying HRs for overweight (BMI between 25 and 30 kg/m2) and obesity (BMI above
30) compared to normal weight (BMI between 20 and 25) at time of ALS diagnosis, adjusted for age at
diagnosis, diagnostic delay, riluzole use, and symptom onset site.
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There was a positive association also between ALS survival and BMI increase between age
40 years and diagnosis. An higher increase in BMI was associated with delayed death (HR:
0.92; 95% CI: 0.88–0.97) after adjustment for age at diagnosis, diagnostic delay, riluzole use,
symptom onset site and BMI at diagnosis. No association between BMI change between ages
25 and 40 (before diagnosis) and ALS survival was noted (HR: 1.03; 95% CI: 0.98–1.08) after
adjustment for birth date and diagnostic delay.
6.2.2 Other findings
The study material for Paper III and Paper IV lacked data on important prognostic indicators of
ALS, such as site of onset, time interval between symptom onset and diagnosis, ALSFRS score,
etc. Despite information on survival time of the patients was available, without proper adjust-
ment for these important prognostic indicators any associations noted for the blood biomarkers
or the medication in a survival analysis would not be highly valuable and meaningful. However,
by categorizing the ALS patients as with short disease duration (patients that had died within
one year after diagnosis) or with long disease duration (patients that had survived at least one
year after diagnosis) it was interesting to report whether the noted associations varied for risk
of ALS with short duration compared to ALS with long duration. The choice of one year as the
cutoff for ALS duration was based on the median survival time given the lack of any clinically
relevant value.
Paper III states that 498 AMORIS participants were diagnosed with ALS and died during
the study follow-up (80% of the participants diagnosed with ALS during the study follow-up).
In this data the associations between the blood biomarkers and ALS risk were stronger for ALS
with short duration (Table 6.2).
Table 6.2: HRs and 95% CIs of ALS with short disease duration (≤1 year between date of ALS diagnosis and
date of death) for biomarkers of carbohydrate, lipid, and apolipoprotein metabolism, after adjustment for sex, age
at measurement, fasting status, occupation and country of birth, a more than 20 year follow-up of the Swedish
AMORIS Study.
Person-years No. of ALS cases HR (95%CI)
Biomarkers of carbohydrate metabolism
Glucose (mmol/L) 9 825 124 197 0.93 (0.82-1.06)
Biomarkers of lipid metabolism
HDL-C (mmol/L) 3 796 795 99 0.70 (0.44-1.11)
LDL-C (mmol/L) 3 799 069 100 1.29 (1.09-1.52)
LDL-C/HDL-C ratio 3 783 328 99 1.09 (1.00-1.18)
Biomarkers of apolipoprotein metabolism
ApoA-I (g/L) 3 392 838 88 0.59 (0.23-1.52)
ApoB (g/L) 3 124 499 83 2.63 (1.58-4.36)
ApoB/ApoA-I ratio 2 898 966 78 2.76 (1.66-4.60)
Paper IV states that 1,841 ALS cases (74% of total number of cases) died during the study
period. The inverse association between prescription of antidiabetics and ALS risk was more
evident for ALS with long disease duration, though antidiabetics may also reduce the risk of
ALS with short disease duration (Table 2 in Paper IV). Similar conclusions apply to the positive
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association between prescription of statins and ALS risk. The association seemed to be due to
ALS with long disease duration, though the results for long and short disease duration were
not statistically different (Table 3 in Paper IV).
Chapter 7
DISCUSSION
7.1 INTERPRETATION OF THE FINDINGS
7.1.1 Diabetes (Paper I)
The study described in Paper I confirmed that type 2 diabetes is associated with future risk
of ALS. A recent Danish study [126] has also supported this finding by suggesting that the
contradicting results on premorbid diabetes presented in earlier different studies [81, 127, 128]
can potentially be explained by type 1 and type 2 diabetes having different associations with
risk of ALS [129].
The reason underlying this association has not yet been clarified. Though lifestyle fac-
tors may partially confound this association it is likely that alterations in the carbohydrate
metabolism may have a beneficial effect on motor neurons survival.
The strongest inverse association of diabetes with ALS risk was reported more than 5
years before the ALS diagnosis. Several hypotheses could explain this finding. For instance,
long-lasting diabetes may involve more pronounced changes to the energy metabolism than
recently developed diabetes. Alternatively, given that medication use may result in assumption
of protective substances, long term use of antidiabetics provides a rather natural explanation
for the observed association. It is also possible that in the presymptomatic phase of the disease
the patients affected by ALS experience a increase of the blood glucose level and some develop
diabetes. Despite this hypothesis may seem conflicting with diabetes being protecting against
the development of ALS, the fact that a factor is associated with a reduced risk of a disease does
not exclude that the same factor may constitute a symptom during the course of the disease.
7.1.2 BMI and BMI change (Paper II)
Interest in studying BMI in relation to ALS started after noticing that a more rapid reduction
in BMI after ALS diagnosis was associated with faster rate of progression and shorter survival.
It is known that BMI at ALS diagnosis is positively associated with survival [2, 67–70] and
a couple of prospective studies have now suggested that low pre-diagnosis BMI is associated
with an increased risk of ALS [77, 78]. The relationship between premorbid BMI, premorbid
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BMI change and ALS survival has however not been studied extensively yet.
The main novel results in Paper II were that low BMI at age 40 corresponded to an increased
risk of ALS and the association was stronger for cases with diagnostic delay shorter than 1 year.
Also, stable or decreasing BMI between age 25 and 40 was associated with a higher risk of ALS
compared to an increasing BMI, regardless of the achieved weight.
Premorbid BMI and BMI change did not seem to predict survival of ALS patients. However,
though a strong association is unlikely, true lack of association is not the only possible expla-
nation for these null findings. Indeed statistical power for these analysis may be limited by the
relatively lower variation of BMI among the veterans compared to other populations.
7.1.3 Carbohydrate, lipid and apolipoprotein metabolisms (Paper III)
Paper II provided the first evidence that high serum levels of apoB and the apoB/apoA-I ratio
are associated with increased risk of ALS. The results on serum LDL-C and the LDL-C/HDL-C
ratio also contribute more evidence about the previously reported inverse association between
ALS and antecedent dyslipidemia [3]. Despite several studies have assessed dyslipidemias in
ALS patients reporting contradicting results [58, 103, 130–133], the lipid profile before the
disease onset has been addressed more rarely [3]. Furthermore, the inverse association between
type 2 diabetes and ALS risk is supported by the finding that high levels of serum glucose are
associated with reduced ALS risk.
The observed trends over time of the biomarkers of lipid and apolipoprotein metabolisms
suggest that patients with ALS may differ from controls already during 20 years before diagnosis
and that something, likely secondary to ALS, happened during the 10 years before diagnosis.
Interestingly, the strongest deviation from the expected trend in a comparable population is
the marked increase in apoA-I levels during the 10 years before diagnosis.
Therefore, among the examined blood biomarkers of carbohydrate, lipid and apolipoprotein
metabolisms there might be both risk factors (e.g. apoB) and biomarkers indicating metabolic
alteration that occur early during the development of ALS (e.g. apoA-I).
7.1.4 Antidiabetics and statins (Paper IV)
Paper IV provided the first epidemiological evidence that different types of antidiabetics have a
similar inverse associations with ALS risk. Furthermore the suggestion that the inverse associa-
tion may be due to use of antidiabetics for more than 8 years is overlapping with the observed
inverse association between long-term diabetes and ALS risk. Diabetes is usually treated and
disentangling the effect of the disease from the effect of the medications is not trivial. However,
the similar associations found for different types of antidiabetics suggest that either diabetes
itself or a common feature across the options for treatment of diabetes is protective against
ALS.
Paper IV is also the first study to provide an extensive description of the prescription of
statins before ALS in a nationwide sample. An increase in prescriptions of statins was identified
during the year before diagnosis, but not during the previous years. The increase was more
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marked among women, possibly because they had a lower baseline risk of receiving a prescrip-
tion of statins. No clear difference was reported across different types of statins. Though statins
were found not to accelerate disease progression [134], these findings suggest that an increase
in lipid levels may be a symptom of the disease. Furthermore, the increased risk of myopathy
following the use of statins may aggravate or draw the attention to early ALS symptoms [135].
The study of both antidiabetics and statins in the same population is a strength. Indeed
patients using antidiabetics or statins may have similar contact with health care and comparable
risk of complications. Furthermore the combined use of antidiabetics and statins is rather
common in patients with type 2 diabetes. If the association observed for antidiabetic were due
to patients with diabetes being more likely to experience competing risk, a similar effect might
have been present also for statins. Conversely if the increase in prescriptions of statins during
the year before diagnosis were due entirely to surveillance bias, a similar effect might have been
expected also for antidiabetics. The different results observed confirm that the associations of
antidiabetics and statins with ALS risk deserve attention. The interpretation needs to be careful
because of the potential confounding by indication.
7.2 CONCLUSIONS AND IMPLICATIONS
The studies discussed in this thesis contribute important new knowledge about the metabolism
of ALS patients before the onset of motor symptoms. However, some limitations subsist and
some questions remain open.
7.2.1 Strengths
The studies included in this thesis represent a valuable contribution to the epidemiology of
ALS. All studies represent the largest of their kind and are based on high-quality data.
Register-based nationwide studies allowed high statistical power without introducing het-
erogeneity in terms of exposure assessment because it was possibly to include a large number
of relatively homogeneous patients over a short time interval. Paper I, Paper III, and Paper IV
share a portion of the patients with ALS included. This characteristic allowed a better compari-
son and interpretation of the findings, compared to the assessment of the different hypotheses
in distinct and heterogeneous populations.
Furthermore, high-quality data was used for the ascertainment of ALS. First, the medical
records of the patients in the National Registry of Veterans with Amyotrophic Lateral Sclerosis
have been reviewed by neurologists specialized in motor neuron diseases to validate the diagno-
sis of ALS. Secondly, the validation study included in Paper III confirmed that, although a very
small proportion of the motor neuron disease identified might have primary lateral sclerosis
or progressive muscular atrophy, the positive predictive value and therefore the specificity of
the diagnosis of ALS in the Swedish National Patient Register is very high.
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7.2.2 Limitations
Though in Paper II and Paper IV some information on family history of ALS was available, the
main limitation of the studies presented in this thesis is the lack of possibility to examine the
role of different ALS genes. Similarly, detailed information on the clinical features of the ALS
patients was only available for the US veterans, while the Swedish studies could not include
important aspects of the clinical history of the patients such as the date of symptom onset.
Furthermore, some of the definitions of exposures used may be prone to misclassification.
This is the case of diabetes diagnosis defined from hospital care or use of statins assessed over
a relative short time interval before index date. However, the misclassification introduced is
likely non-differential for ALS patients and other participants so that the reported associations
may represent conservative estimates of the real associations.
7.2.3 Implications
This work generates new scientific hypotheses. Alterations in the carbohydrate, lipid and
apolipoprotein metabolisms are associated with ALS risk and may serve as prodromal symptoms
decades before ALS diagnosis.
In particular, the novel results on the involvement of apolipoprotein metabolism indicates
that imbalance between apoB and apoA-I as well as between LDL-C and HDL-C may be an
etiologic mechanism for ALS and needs to be further studied.
Furthermore, the increase in statin prescriptions before ALS diagnosis and the protective
effect found in individuals with diabetes suggest that pharmacological treatment may have a
role in the etiology of ALS.
The observations that the association of BMI is stronger for ALS with short diagnostic
delay (Paper II) and the associations of blood biomarkers (Paper III) and drugs (Paper IV)
seem to be stronger for disease with longer survival highlight that ALS have likely different
etiologies. As previously suggested, susceptibility to certain risk factors may correlate with
disease characteristics.
All the studies indicate that patients with ALS may have already signs of abnormal energy
metabolism several years (or decades) before the onset of motor symptoms. The death of the
motor neurons in the nervous system and its devastating consequences on motor skills may be
only a rather late result of a number of preceding events taking place in the whole body. These
cascades of events seem to start earlier than previously believed.
Chapter 8
FUTURE PERSPECTIVES
The reasons for abnormalities in metabolism contributing to the disease need to be identified
and contrasted. Future studies aimed to clarify the potential modifiable effect of metabolic
changes in the course of ALS are warranted.
Current attempt of treatment indicates that targeting secondary pathological events may
not be able to stop the disease progression and understanding the early events in the disease
course may be a necessary step for effectively interrupting the cascade of pathological events.
The integration of quality registers, biological specimens, and cutting-edge technology and
analytical approaches is needed to characterize the diverse etiologies of ALS.
Whether weight loss or use of statins accelerate the development of ALS should be further
investigated. For instance more careful strategies to achieve a healthy weight and alternative
lipid-modulating approaches have the potential to prevent or delay the occurrence of this
disease in some individuals.
Why individuals with high apoB are at higher risk of developing ALS remains unclear.
Investigating whether alterations in the apolipoprotein metabolism have direct detrimental
effects leading to degeneration of motor neurons or whether this feature is a consequence of
other risk factors would provide further insight in the etiological process of ALS.
The studies described in this thesis also highlight the importance of considering that dif-
ferent subgroups of ALS patients may present different metabolic alterations or being more
susceptible to their effect. In particular age and sex differences deserve attention. Further-
more, the metabolic profile may correlate with other important factors such as diagnostic delay
and rate of disease progression. Disentangling the role of genetic predisposition and gene-
environment interactions will be an essential step to fully appreciate the nature of metabolic
changes in ALS.
Furthermore, as a neurodegenerative disease with a relatively strong clinical diagnostic
certainty, compared to Alzheimer’s and Parkinson’s diseases, ALS is an excellent model disease
for research. Therefore, the new hypotheses generated by studying ALS should be instrumental
for identifying common and peculiar features of these diseases and help disentangling the
complex mechanisms of neurodegeneration, which is becoming more and more of concern in
the developed countries.
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